> ## Content Index
> Fetch the complete content index at: https://bioweek.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Will Review the First In Vivo CRISPR Therapy Without a Public Panel
- URL: https://bioweek.com/fda-will-review-the-first-in-vivo-crispr-therapy-without-a-public-panel/
- Published: 2026-10-02T05:04:49.000Z
- Updated: 2026-10-02T05:04:49.000Z
- Description: Intellia's lonvo-z is on a priority-review track to March 10, 2027 with no advisory committee planned. The one-dose gene edit cut HAE attacks 87% in Phase 3, and the debate over permanence, competition, and price will happen largely out of view.
- Author: BioWeek
- Tags: Pipeline, Science

The Food and Drug Administration has [accepted](https://www.biospace.com/press-releases/intellia-therapeutics-announces-fda-acceptance-of-biologics-license-application-with-priority-review-for-lonvoguran-ziclumeran-lonvo-z-for-hereditary-angioedema-hae?ref=bioweek.com) Intellia Therapeutics' Biologics License Application for lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002) and granted Priority Review, with a PDUFA target action date of March 10, 2027\. The agency is also not currently planning an advisory committee on the application. If approved, lonvo-z would be the world's first in vivo CRISPR-based therapy and the only one-time treatment for hereditary angioedema.

Skipping a public panel is a procedural choice, not a verdict, but it changes the review. A permanent genome edit that cannot be withdrawn like a monoclonal antibody will be judged inside the agency, without the open debate that usually accompanies first-in-class medicines.

### What HAELO actually showed

The Phase 3 HAELO trial, [published](https://www.nejm.org/doi/full/10.1056/NEJMoa2600931?ref=bioweek.com) in the New England Journal of Medicine on June 12, 2026 (NCT06634420), randomized 80 patients 2:1 to a single intravenous 50 mg infusion of lonvo-z (52) or placebo (28). Monthly attack rate from weeks 5 through 28 fell from 2.10 (95% CI 1.55 to 2.86) on placebo to 0.26 (95% CI 0.15 to 0.45) on lonvo-z, a relative difference of -87% (95% CI -93 to -78), P<0.001.

Intellia's [release](https://www.biospace.com/press-releases/intellia-therapeutics-announces-fda-acceptance-of-biologics-license-application-with-priority-review-for-lonvoguran-ziclumeran-lonvo-z-for-hereditary-angioedema-hae?ref=bioweek.com) added a louder figure: 62% of lonvo-z patients were entirely attack-free and HAE therapy-free for the six-month efficacy period, versus 11% of placebo patients (p<0.0001), and all lonvo-z patients remained free from long-term prophylaxis as of the same cutoff. The trial enrolled its 80 patients in nine months.

Safety in the pivotal window was quiet. Adverse events occurred in 92% of lonvo-z patients versus 86% on placebo, with no serious or grade 3 or higher events in the lonvo-z group; infusion-related reactions, headache, and fatigue were the most common events higher on lonvo-z, all mild or moderate. That profile makes an AdComm skip look like confidence rather than haste.

### A permanent edit in a market that already works

HAE affects an estimated 1 in 50,000 people, with severe, recurring, unpredictable swelling attacks that can be painful, debilitating, and life-threatening. Prophylaxis is lifelong: chronic intravenous or subcutaneous dosing as often as twice per week, or daily orals, and breakthrough attacks can still occur. Kallikrein inhibition is a clinically validated strategy, so lonvo-z is not a leap into an untested pathway. It is a leap in duration.

Lonvo-z is intended to permanently lower kallikrein by inactivating the kallikrein B1 (KLKB1) gene with a single outpatient dose. It is an mRNA-lipid nanoparticle medicine that delivers transient Cas9 expression, rebalancing the kallikrein-kinin system by reducing prekallikrein levels rather than targeting C1 inhibitor, the protein whose deficiency causes Type 1 and Type 2 HAE. The program holds FDA Orphan Drug and RMAT designations.

That mechanism lands in a crowded field: lanadelumab (Takeda) reported Phase 3 preventive data in JAMA in 2018, garadacimab (CSL) in The Lancet in 2023, and berotralstat (BioCryst) in 2020\. Those products can be stopped, switched, or dose-adjusted; lonvo-z offers the opposite bargain, leaving chronic therapy in exchange for an irreversible genomic change. For a patient exhausted by twice-weekly injections, that trade may be obvious; for a patient stable on a daily pill, it is a harder call. FDA will have to decide whether the label positions it as a last resort or a first-line alternative.

### Follow-up is longer than the pivotal window, and still incomplete

An October 1, 2026 interview-based [report](https://www.bioxconomy.com/modalities/in-vivo-crispr-treatment-for-hereditary-angioedema-clears-phase-iii-receives-bla-approval?ref=bioweek.com) said follow-up of lonvo-z patients has now lasted over four years with no off-target effects observed, though no liver biopsies were performed. Only at very high preclinical doses, up to 50 times the Phase 1 dose, was a very small off-target risk seen in an intron of a MAP kinase gene, and animal studies showed no germline alterations. The lead investigator says the chance redosing is needed at the optimal 50 mg dose is extremely low.

Independent clinicians still caution that a durable, irreversible intervention requires registries and vigilance for rare or delayed safety signals. That is the tension the missing panel would have aired in public: the pivotal dataset is short relative to the claim of permanence, and the longer follow-up, though encouraging, is not biopsy-confirmed. FDA can require post-marketing infrastructure without a panel. It cannot recreate the public airing of residual risk.

### The price of never dosing again

Genome-editing therapies have historically hit some of the industry's highest price points: exa-cel (Casgevy, CRISPR Therapeutics/Vertex), for sickle cell disease and beta thalassemia, was priced at $2.2 million, and access concerns are already being raised for one-time editing therapies. Unlike that ex vivo product, which requires chemotherapy preconditioning, lonvo-z is a 2 to 4 hour intravenous infusion with no preconditioning, and the commercial template still points toward a multi-million-dollar charge.

A therapy that removes twice-weekly injections can still fail patients if payers treat it as a luxury relative to lanadelumab, garadacimab, or berotralstat. Priority Review to March 10, 2027 will test whether FDA, and then payers, accept a permanent edit as the logical end of a validated kallikrein strategy, or as an irreversible bet that should wait for more years of follow-up. The data invited the skip. The product's permanence is why some clinicians will still wish the debate had been public.